Biodexa Pharmaceuticals annual operating cash flow
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Biodexa Pharmaceuticals Operating Cash Flow Growth & History (BDRX)
Biodexa Pharmaceuticals's operating cash flow was −£5.6M for fiscal 2025.
View full Biodexa Pharmaceuticals company overviewBiodexa Pharmaceuticals annual operating cash flow history
| Fiscal year | Period ended | Operating cash flow | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | −£5.6M | £6.7M | — |
| 2024 | 2024-12-31 | −£12.3M | −£5.4M | — |
| 2023 | 2023-12-31 | −£6.8M | £222,000 | — |
| 2022 | 2022-12-31 | −£7.0M | −£1.0M | — |
| 2021 | 2021-12-31 | −£6.0M | £3.3M | — |
| 2020 | 2020-12-31 | −£9.3M | −£2.8M | — |
| 2019 | 2019-12-31 | −£6.5M | £7.0M | — |
| 2018 | 2018-12-31 | −£13.4M | −£497,000 | — |
| 2017 | 2017-12-31 | −£13.0M | £133,000 | — |
| 2016 | 2016-12-31 | −£13.1M | −£665,000 | — |
| 2015 | 2015-12-31 | −£12.4M | — | — |
Biodexa Pharmaceuticals operating cash flow trends
Over the last five fiscal years, Biodexa Pharmaceuticals's operating cash flow increased from −£9.3M to −£5.6M, a change of £3.7M.
About the metric
What operating cash flow means
Operating cash flow is the cash generated or used by a company’s core operations. It incorporates working-capital movements and other operating cash items, and it is the starting point for calculating free cash flow.
Calculation and source
SEC-reported operating cash flow
TickerStat standardizes net cash provided by or used in operating activities reported in company SEC filings. It is historical filing data before capital expenditures, financing activities, and investing activities. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Biodexa Pharmaceuticals source filings ↗Community posts
Biodexa advances trial enrollment as research spending and cash use rise
Biodexa ($BDRX) reported that 92 of the planned 168 participants have entered its Serenta trial, while first-half research and development spending increased to £2.92 million from £1.67 million. Spending reflected the trial and manufacturin ...